| [1] |
Liang X, Zhang L, Nataraian SK, et al. Proline mechanisms of stress survival [J]. Antioxid Redox Signal, 2013,19(9):998-1011.
|
| [2] |
Phang JM, Pandhare J, Liu Y. The metabolism of proline as microenvironmental stress substrate[J]. J Nutr, 2008,138(10):2008S-2015S.
|
| [3] |
Meng ZH, Lou Z, Liu Z, et al. Crystal structure of human pyrroline-5-carboxylate reductase[J]. J Mol Biol, 2006,359(5):1364-1377.
|
| [4] |
Reversade B, Escande-Beillard N, Dimopoulou A, et al. Mutations in PYCR1 cause cutis laxa with progeroid features[J]. Nat Genet, 2009, 41(9):1016-1021.
|
| [5] |
Lin DS, Yeung CY, Liu HL, et al. A novel mutation in PYCR1 causes an autosomal recessive cutis laxa with premature aging features in a family[J]. Am J Med Genet A, 2011,155A(6):1285-1289.
|
| [6] |
Scherrer DZ, Baptista MB, Matos AH, et al. Mutations in PYCR1 gene in three families with autosomal recessive cutis laxa, type 2[J]. Eur J Med Genet, 2013,56(6):336-339.
|
| [7] |
Kretz R, Bozorgmehr B, Kariminejad MH, et al. Defect in proline synthesis: pyrroline-5-carboxylate reductase 1 deficiency leads to a complex clinical phenotype with collagen and elastin abnormalities[J]. J Inherit Metab Dis, 2011,34(3):731-739.
|
| [8] |
Sun T, Song Y, Yu H, et al. Identification of lncRNA TRPM2-AS/miR-140-3p/PYCR1 axis's proliferates and anti-apoptotic effect on breast cancer using co-expression network analysis[J]. Cancer Biol Ther, 2019,20(6):760-773.
|
| [9] |
Hollinshead KER, Munford H, Eales KL, et al. Oncogenic IDH1 Mutations Promote Enhanced Proline Synthesis through PYCR1 to Support the Maintenance of Mitochondrial Redox Homeostasis[J]. Cell Rep, 2018,22(12):3107-3114.
|
| [10] |
Dimopoulou A, Fischer B, Gardeitchik T, et al. Genotype-phenotype spectrum of PYCR1-related autosomal recessive cutis laxa[J]. Mol Genet Metab, 2013,110(3):352-361.
|
| [11] |
Ritelli M, Palit A, Giacopuzzi E, et al. Clinical and molecular characterization of a 13-year-old Indian boy with cutis laxa type 2B: Identification of two novel PYCR1 mutations by amplicon-based semiconductor exome sequencing[J]. J Dermatol Sci, 2017, 88(1):141-143.
|
| [12] |
Gardeitchik T, Mohamed M, Fischer B, et al. Clinical and biochemical features guiding the diagnostics in neurometabolic cutis laxa[J]. Eur J Hum Genet, 2014,22(7):888-895.
|
| [13] |
Guernsey DL, Jiang H, Evans SC, et al. Mutation in pyrroline-5-carboxylate reductase 1 gene in families with cutis laxa type 2[J]. Am Hum Genet, 2009,85(1):120-129.
|
| [14] |
Eduard AS, Erwin EWJ, Gajja SS. Human pyrroline-5-carboxylate reductase (PYCR1) acts on Δ1-piperideine-6-carboxylate generating L-pipecolic acid[J]. J Inherit Metab Dis, 2014, 37(3):327-332.
|
| [15] |
Elia I, Broekaert D, Christen S, et al. Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells[J]. Nat Commun, 2017,8:15267.
|
| [16] |
Phang JM, Liu W, Hancock CN, et al. Proline metabo-lism and cancer: Emerging links to glutamine and collagen[J]. Curr Opin Clin Nutr Metab Care, 2015,18(1):7177.
|
| [17] |
Liu W, Phang JM. Proline dehydrogenase (oxidase) in cancer[J]. Biofactors, 2012,38(6):398406.
|
| [18] |
Krishnan N, Dickman MB, Becker DF. Proline modulates the intracellular redox environment and protects mammalian cells against oxidative stress[J]. Free Radic Biol Med, 2008,44(4):671-681.
|
| [19] |
Chen SY, Yang X, Yu M, et al. SIRT3 regulates cancer cellproliferation through deacetylation of PYCR1 in proline metabolism[J]. Neoplasia, 2019,21(7):665-675.
|
| [20] |
Craze ML, Cheung H, Jewa N, et al. MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer[J]. Br J Cancer, 2018,118(2):258-265.
|
| [21] |
Possemato R, Marks KM, Shaul YD, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer[J]. Nature, 2011,476(7360):346-350.
|
| [22] |
Ding JF, Kuo ML, Su LL, et al. Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers[J]. Carcinogenesis, 2017,38(5):519-531.
|
| [23] |
Cai F, Miao YY, Liu CY, et al. Pyrroline5carboxylate reductase 1 promotes proliferation and inhibits apoptosis in nonsmall cell lung cancer[J]. Oncology Letters, 2018,15(1):731-740.
|
| [24] |
Yang SC, Liu Y, Li MY, et al. FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer[J]. Mol Cancer, 2017,16(1):124.
|
| [25] |
Wang DC, Wang LC, Zhang Y, et al. PYCR1 promotes the progression of non-small-cell lung cancer under the negative regulation of miR-488[J]. Biomed Pharmacother, 2019,111:588-595.
|
| [26] |
Jariwala U, Prescott J, Jia L, et al. Identification of novel androgen receptor target genes in prostate cancer[J]. Mol Cancer, 2007,6:39.
|
| [27] |
Ernst T, Hergenhahn M, Kenzelmann M, et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue[J]. Am J Pathol, 2002,160(6):2169-2180.
|
| [28] |
Zeng T, Zhu L, Liao M, et al. Knockdown of PYCR1 inhibits cell proliferation and colony formation via cell cycle arrest and apoptosis in prostate cancer[J]. Med Oncol, 2017,34(2):27.
|
| [29] |
Fu WJ, Xie ZB, Zheng SF, et al. The clinical significance of PYCR1 expression in renal cell carcinoma[J]. Medicine, 2019,98(28):e16384.
|
| [30] |
Zhuang JH, Song YN, Ye Y, et al. PYCR1 interference inhibits cell growth and survival via cJun Nterminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer[J]. J Transl Med, 2019,17(1):343.
|